Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy |
| |
| Authors: | H Y S Ngan Raymond H S Liang W K Lam T K Chan |
| |
| Institution: | (1) Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong;(2) Department of Obstetrics and Gynaecology, University of Hong Kong, Queen Mary Hospital, Pokfu n Road, Hong Kong |
| |
| Abstract: | Subclinical and clinical bleomycin-induced pulmary toxicity (BIP) were investigated retrospectively in 9 patients with non-Hodgkin's lymphoma treated by mbination chemotherapy containing bleomycin. A crease in carbon monoxide diffusing capacity (DLCO) is found in 12.8% of patients. The cumulative risk of normal DLCO increased with the increasing total cumulive dose of bleomycin. No significant difference in the e of BIP was observed between patients receiving bleovein/Adriamycin/cyclophosphamide/vincristine/prednine (BACOP; bleomycin given at 10 mg/m2 for 4 weeks) d bleomycin/Adriamycin/cyclophosphamide/vincrise/dexamethasone/methotrexate/folinic acid (mACOD; bleomycin given at 4 mg/m2 for 3 weeks, ethotrexate given at 200 mg/m2. Monitoring for subclinil BIP should be considered in patients with non-Hodg lymphoma even if only a low dose of bleomycin was ven in the presence of other chemotherapeutic agents. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
